>>Signaling Pathways>> MAPK Signaling>> RSK>>Pluripotin

Pluripotin (Synonyms: SC1)

Catalog No.GC17407

Pluripotin은 각각 98nM 및 212nM의 KD를 갖는 ERK1 및 RasGAP의 이중 억제제입니다. Pluripotin은 또한 각각 0.5, 2.5, 3.3 및 10.0μM의 IC50으로 RSK1, RSK2, RSK3 및 RSK4를 억제합니다.

Products are for research use only. Not for human use. We do not sell to patients.

Pluripotin Chemical Structure

Cas No.: 839707-37-8

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$108.00
재고 있음
2mg
US$59.00
재고 있음
5mg
US$89.00
재고 있음
10mg
US$158.00
재고 있음
25mg
US$315.00
재고 있음
50mg
US$558.00
재고 있음
100mg
US$720.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Pluripotin is a dual inhibitor of ERK1 and RasGAP with KDs of 98 nM and 212 nM, respectively. Pluripotin also inhibits RSK1, RSK2, RSK3, and RSK4 with IC50s of 0.5, 2.5, 3.3, and 10.0 µM, respectively.

Pluripotin (SC-1) inhibits Abl1, p70S6K, PLK2, RSK1, RSK2, RSK3, RSK4 with IC50s of 0.005, 1.4, 2.2, 0.5, 2.5, 3.3, 10.0 µM,respectively. Pluripotin (SC-1) decreases cell growth for 7 colon tumor cell lines. After a five day exposure to 0.1 µM SC-1, the seven colon tumor lines are evaluated for changes in cell number and viability. There is a statistically significant decrease in cell number but >95% viability[2].

References:
[1]. Chen S, et al. Self-renewal of embryonic stem cells by a small molecule. Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17266-71.
[2]. Mertins SD, et al. A small molecule (pluripotin) as a tool for studying cancer stem cell biology: proof of concept. PLoS One. 2013;8(2):e57099.

리뷰

Review for Pluripotin

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Pluripotin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.